In addition, I am pushing for reforms to make improvements in price transparency and increase access to more affordable generic medications.
Push reforms to improve prescription drug price transparency and increase access to more affordable generic medications.
Occurrences
Evidence
Representative Chrissy Houlahan voted to pass H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, and said, “I promised my community that I would fight to lower the high cost of prescription drugs.” She described the bill as making prescription drugs more affordable and said it would create requirements and incentives to expand protections and lower prices across the market.
The House-passed H.R. 3 required HHS to negotiate prices for certain drugs, including single-source brand-name drugs that do not have generic competition, and it included a drug price transparency title requiring manufacturers to report specified information for certain high-cost drugs.
Houlahan said the Build Back Better Act would, “for the first time in history,” empower the government to negotiate lower drug prices under Medicare, cap out-of-pocket spending at $2,000, and require drug companies to pay rebates if prices increase faster than inflation.
Houlahan said the Inflation Reduction Act, signed into law in 2022, included cost-saving provisions helping Pennsylvanians save on health care bills. The page says the law allows Medicare to negotiate directly with pharmaceutical companies for fair prices for prescription drugs and that out-of-pocket drug costs will be capped at no more than $2,000 in 2025.
CMS stated that, “For the first time, the law provides Medicare the ability to directly negotiate the prices of certain high expenditure, single source drugs without generic or biosimilar competition,” and that the negotiated prices would go into effect January 1, 2026, producing an estimated $1.5 billion in savings for people with Medicare Part D coverage.
Assessments
Houlahan materially advanced the promise by voting for and publicly backing major House drug-pricing packages, including H.R. 3 in 2019, which contained prescription-drug transparency provisions and targeted single-source drugs lacking generic competition. She also supported later Democratic legislation whose enacted successor, the 2022 Inflation Reduction Act, delivered significant prescription-drug affordability reforms such as Medicare price negotiation and out-of-pocket caps that took effect after that term. But the evidence here does not show that the full promised outcome was delivered on both fronts, especially increasing access to more affordable generic medications and enacting the broader transparency reforms she supported. Because she contributed to meaningful later reforms but did not clearly secure the full promise, partial credit is the best fit.
Houlahan made documented efforts to advance prescription drug affordability reforms, including voting for H.R. 3 in 2019, which contained drug price negotiation and transparency provisions related to drugs without generic competition. A major portion of the broader affordability goal was later enacted through the Inflation Reduction Act, including Medicare drug price negotiation, inflation-related controls, and a Part D out-of-pocket cap. However, the evidence does not show full delivery of the specific promise to improve prescription drug price transparency and increase access to more affordable generic medications across the market; the enacted reforms mainly address Medicare negotiation and consumer cost caps rather than a comprehensive transparency and generic-access outcome. This supports partial fulfillment, delivered in a later term.